AstraZeneca's Kendall Square R&D center in Cambridge, MA. (Credit: Pickard Chilton)
November 12, 2024 07:08 AM ESTUpdated 08:07 AM
R&D
Manufacturing

As­traZeneca bud­gets an­oth­er $2B to boost man­u­fac­tur­ing and R&D in US

Anna Brown

News Reporter

Among a flur­ry of third-quar­ter up­dates on Tues­day, As­traZeneca said it is ear­mark­ing an ad­di­tion­al $2 bil­lion to add 1,000 new …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times